CAM
TBPH icon

Cormorant Asset Management’s Theravance Biopharma TBPH Stock Holding History

Cormorant Asset Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-300,000
Closed -$4.36M – 102
2021
Q2 		$4.36M Sell
300,000
-250,000
-45% -$4.69M 0.15% 86
2021
Q1 		$11.2M Hold
550,000
– – 0.25% 69
2020
Q4 		$9.77M Sell
550,000
-100,072
-15% -$1.8M 0.23% 67
2020
Q3 		$9.61M Buy
650,072
+550,072
+550% +$10.3M 0.37% 60
2020
Q2 		$2.1M Hold
100,000
– – 0.08% 76
2020
Q1 		$2.31M Buy
100,000
+50,000
+100% +$1.25M 0.11% 67
2019
Q4 		$1.29M Buy
+50,000
New +$972K 0.05% 66
2019
Q1 		– Sell
-884,916
Closed -$22.6M – 73
2018
Q4 		$22.6M Sell
884,916
-215,084
-20% -$5.81M 1.84% 17
2018
Q3 		$35.9M Sell
1,100,000
-200,000
-15% -$5.45M 2.34% 16
2018
Q2 		$29.5M Hold
1,300,000
– – 2.18% 16
2018
Q1 		$31.5M Buy
1,300,000
+400,000
+44% +$11M 2.35% 11
2017
Q4 		$25.1M Sell
900,000
-50,000
-5% -$1.48M 2.63% 11
2017
Q3 		$32.5M Hold
950,000
– – 5.74% 5
2017
Q2 		$37.8M Sell
950,000
-475,000
-33% -$18.3M 6.27% 2
2017
Q1 		$52.5M Hold
1,425,000
– – 7.62% 1
2016
Q4 		$45.4M Buy
1,425,000
+306,628
+27% +$9.51M 6.12% 2
2016
Q3 		$40.5M Hold
1,118,372
– – 4.47% 3
2016
Q2 		$25.4M Buy
+1,118,372
New +$24.2M 3.6% 7

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Cormorant Asset Management's TBPH Position: Q3 2021 in Review

Cormorant Asset Management sold out of Theravance Biopharma (TBPH) in Q3 2021, closing a stake of 300,000 shares — an estimated $4.36M sold.

Cormorant Asset Management first reported a position in TBPH in Q2 2016 and held it in 18 quarters. The position peaked at $52.5M in Q1 2017. 119 funds tracked by Wall St. Rank hold TBPH as of Q3 2021.

  • Cormorant Asset Management reported no remaining Theravance Biopharma position as of Q3 2021 after selling out during the quarter.
  • Cormorant Asset Management sold 300,000 Theravance Biopharma shares in Q3 2021, an estimated $4.36M.
  • Cormorant Asset Management first reported a position in Theravance Biopharma in Q2 2016 and held it in 18 quarters.
  • Cormorant Asset Management's Theravance Biopharma position peaked at $52.5M in Q1 2017.
  • 119 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2021.

Based on Cormorant Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.